ABK Biomedical

ABK Biomedical

Private
Halifax, Nova ScotiaHealthcare & Life Scienceshttps://www.abkbiomedical.com

Last Round

Series D

Oct 14, 2025

Total Funding Raised

$107.61M

Momentum Score

25 /100

Company Overview

ABK Biomedical is a medical technology company that develops innovative microspheres to enhance the treatment of hypervascular tumors through improved targeting of tumor vascularity and tissue.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials, Medical Imaging

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

embolic microspheresradioembolizationembolic therapiesYttrium-90 microspheresliver cancer treatmentinterventional radiologyinterventional oncologyTARESIRTembolizationmedical deviceuterine fibroid embolizationUFEembolic beadshypervascular tumorsFDA Breakthrough Device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ABK Biomedical Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ABK Biomedical Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series DOct 14, 2025
Series CDec 6, 2022
Series BApr 8, 2019
GrantFeb 22, 2018
Series AAug 1, 2017
Seed
Oct 24, 2012

Key People

Founding team and executive leadership

Michael Mangano

President And CEO, Member Board Of Directors

Executive Team

Mike Tyson

CFO

Executive Team

ABK Biomedical Investors

Notable investors and investment history

InvestorRounds
InnovacorpSeed, Series A
F-Prime CapitalSeries C, Series D, Series B
Eight Roads VenturesSeries C, Series D
InnovacorpSeed
Santé VenturesSeries D
Atlantic Canada Opportunities AgencyGrant, Seed
F-Prime CapitalSeries D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 8, 2026

    Building a plant in Missouri for Eye90 microsphere technology.

  • Apr 8, 2026

    Partnering with COR Development to build a GMP facility in Missouri.

ABK Biomedical Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ABK Biomedical Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ABK Biomedical's valuation, stock price, and market status.

Firmographic Details

HeadquartersHalifax, Nova Scotia
Employee Range42
Year Founded2012
Last FundingOct 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.